Zobrazeno 1 - 1
of 1
pro vyhledávání: '"E. Karaselimovic‐Dzambasovic"'
Autor:
Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz‐Rosiak, Soo Yeon Cheong, Jeehoon Ghil, S. Sokolovic, M. Mekic, N. Prodanovic, B. Gajic, E. Karaselimovic‐Dzambasovic, B. Pojskic, A. Toncheva, P. Dimitar, L. Rodina, M. Geneva‐Popova, I. Staykov, R. Stoilov, L. Podrazilova, Z. Mosterova, G. Simkova, J. Kopackova, Z. Stejfova, J. Vencovsky, Z. Urbanova, L. Janska, D. Galatíkova, S. Stropuviene, I. Sniuoliene, K. Sitek‐Ziolkowska, M. Rell‐Bakalarska, R. Kolasa, S. Daniluk, B. Sliwowska, M. Bartosik‐Twardowska, J. Brzezicki, M. Konieczny, S. Jeka, J. Choe, S. Bae, Y. Kang, L. Prystupa, Z. Vyacheslav, I. Gasanov, R. Yatsyshyn, D. Rekalov, O. Iaremenko, M. Stanislavchuk, V. Tseluyko
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd57157bedc7b756d3a592490108b340
https://doi.org/10.1002/art.40336
https://doi.org/10.1002/art.40336
